Limits...
The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds

View Article: PubMed Central - HTML

No MeSH data available.


© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3112868&req=5

Mentions: The EuResist combined system performance in predicting the correct virological success of a TCE after 8-weeks (validation set, n=561) exhibited an area under the receiver operating characteristic (AUROC) of 0.8 (whereas Stanford HIVdb GIS assessed to 0.73, p=0.002). The inclusion of therapy history, clinical, and demographic covariates was shown to increase significantly prediction performance. In the subset of regimens containing RAC (n=151), the EuResist AUROC was 0.7 and Stanford HIVdb AUROC was 0.63, not allowing to assess a significant difference owing to the small sample size. See Figure 1.


The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3112868&req=5

Mentions: The EuResist combined system performance in predicting the correct virological success of a TCE after 8-weeks (validation set, n=561) exhibited an area under the receiver operating characteristic (AUROC) of 0.8 (whereas Stanford HIVdb GIS assessed to 0.73, p=0.002). The inclusion of therapy history, clinical, and demographic covariates was shown to increase significantly prediction performance. In the subset of regimens containing RAC (n=151), the EuResist AUROC was 0.7 and Stanford HIVdb AUROC was 0.63, not allowing to assess a significant difference owing to the small sample size. See Figure 1.

View Article: PubMed Central - HTML

No MeSH data available.